You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

GSK573719

Showing 1 - 25 of 45
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Asthma Trial (FF/UMEC/VI, ELLIPTA, FF/VI)

Not yet recruiting
  • Asthma
  • (no location specified)
Feb 24, 2023

Hyperhidrosis Trial in Raleigh, Austin, Montreal (Umeclidinium, Vehicle)

Completed
Has Results
  • Hyperhidrosis
  • Raleigh, North Carolina
  • +2 more
Sep 11, 2018

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK573719 125mcg, GSK573719 250mcg, GSK573719 500mcg)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719 125mcg
  • +3 more
  • Madisonville, Kentucky
  • +19 more
Feb 8, 2018

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • 125/25 mcg once-daily GSK573719/GW642444
  • +2 more
  • Mobile, Alabama
  • +53 more
Apr 30, 2018

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GSK573719 125)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719/GW642444 125/25
  • +5 more
  • Jasper, Alabama
  • +52 more
Jan 18, 2018

Pulmonary Disease, Chronic Obstructive Trial in United States (GSK573719, Tiotropium, Placebo)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719
  • +2 more
  • Costa Mesa, California
  • +12 more
Oct 9, 2017

Asthma Trial in Worldwide (Placebo, UMEC, Fluticasone Furoate)

Completed
Has Results
  • Asthma
  • Placebo
  • +3 more
  • Tempe, Arizona
  • +69 more
Oct 6, 2020

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (62.5/25mcg, 62.5mcg, 25mcg)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Tucson, Arizona
  • +164 more
Aug 2, 2018

Pulmonary Disease, Chronic Obstructive Trial in United States (500mcg/25mcg once daily, Placebo once daily)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • 500mcg/25mcg once daily
  • Placebo once daily
  • Chester, South Carolina
  • +3 more
Oct 9, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK573719/GW642444 125/25, GSK573719/GW642444 62.5/25, GW642444)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719/GW642444 125/25
  • +3 more
  • Birmingham, Alabama
  • +96 more
Jan 18, 2018

Pulmonary Disease, Chronic Obstructive Trial in Germany, Japan, United States (GSK573719, Placebo)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719
  • Placebo
  • Sunset, Louisiana
  • +26 more
Oct 9, 2017

Asthma Trial in Worldwide (FF/GSK573719, FF, FF/VI)

Completed
Has Results
  • Asthma
  • Saint Louis, Missouri
  • +31 more
Sep 7, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK 573719 +GW642444 125/25, GSK573719 + GW642444 62.5/25, GSK 573719

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK 573719 +GW642444 125/25
  • +5 more
  • Phoenix, Arizona
  • +30 more
Oct 9, 2017

Pulmonary Disease, Chronic Obstructive Trial in Kagoshima (GSK573719 250 µg, GSK573719 500 µg, GSK573719 1000 µg)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719 250 μg
  • +3 more
  • Kagoshima, Japan
    GSK Investigational Site
Aug 1, 2017

Pulmonary Disease, Chronic Obstructive Trial in Budapest, Bratislava (Inhaled GSK573719/vilanterol, Inhaled GSK573719)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • Inhaled GSK573719/vilanterol
  • Inhaled GSK573719
  • Budapest, Hungary
  • +1 more
Jul 24, 2017

Pulmonary Disease, Chronic Obstructive Trial in Prague 7, Budapest (Inhaled GSK573719, Inhaled GSK573719/vilanterol)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • Inhaled GSK573719
  • Inhaled GSK573719/vilanterol
  • Prague 7, Czechia
  • +1 more
Jul 24, 2017

Pulmonary Disease, Chronic Obstructive Trial in Hannover, Berlin, Hamburg (GSK573719, Tiotropium)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Hannover, Niedersachsen, Germany
  • +2 more
Aug 21, 2017

Pulmonary Disease, Chronic Obstructive Trial in Berlin (GSK573719)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719
  • Berlin, Germany
    GSK Investigational Site
Aug 2, 2017

Pulmonary Disease, Chronic Obstructive Trial in Germany, United States (Tiotropium, Placebo, GSK573179)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Phoenix, Arizona
  • +18 more
Oct 9, 2017

Pulmonary Disease, Chronic Obstructive Trial in China, Korea, Republic of (Umeclidinium bromide, Placebo)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • Umeclidinium bromide
  • Placebo
  • Guangzhou, Guangdong, China
  • +25 more
Jun 12, 2020

Pulmonary Disease, Chronic Obstructive Trial in London (Placebo Moxifloxacin, Moxifloxacin, GSK573719/Vilanterol 125/25mcg)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • Placebo Moxifloxacin
  • +5 more
  • London, United Kingdom
    GSK Investigational Site
Jun 9, 2017

Pulmonary Disease, Chronic Obstructive Trial in London (GSK573719 (SOLUTION), GSK573719 (INHALATION POWDER))

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719 (SOLUTION)
  • GSK573719 (INHALATION POWDER)
  • London, United Kingdom
    GSK Investigational Site
Jun 26, 2017

Pulmonary Disease, Chronic Obstructive Trial in Worldwide (GSK573719/GW642444 125/25mcg, GSK573719 125mcg, GW642444 25mcg)

Completed
Has Results
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719/GW642444 125/25mcg
  • +3 more
  • Jasper, Alabama
  • +156 more
Jan 25, 2018

Pulmonary Disease, Chronic Obstructive Trial in Berlin (GSK573719 62.5 mcg (one strip), GSK573719 62.5 mcg(two strips),

Completed
  • Pulmonary Disease, Chronic Obstructive
  • GSK573719 62.5 mcg (one strip)
  • +4 more
  • Berlin, Germany
    GSK Investigational Site
Jun 19, 2017

Pulmonary Disease, Chronic Obstructive Trial in London (GSK573719, GW573719/GW573719)

Completed
  • Pulmonary Disease, Chronic Obstructive
  • London, United Kingdom
    GSK Investigational Site
Jun 13, 2017